Close Menu

NEW YORK – Ridgefield, Connecticut-based Boehringer Ingelheim on Tuesday announced pooled data from a collection of randomized clinical trials and real-world studies demonstrating that its TKI afatinib (Gilotrif) is efficacious across EGFR-mutated non-small cell lung cancer patients, regardless of their ethnicity.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.